Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: A meta-analysis

Pan, Xingnan; Zheng, Lian-Qiu; Lai, Xiaohuan

doi:10.3748/wjg.v20.i38.14051

Cited by 45 publications

(30 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before MSCs reach clinical application a number of issues must be addressed. Recent meta-analyses have concluded that although no serious side effects or complications have been reported, and therefore MSC therapy may be considered safe, study methodology is in general deficient, making multicenter randomized prospective trials necessary to develop standardized protocols for MSC transplantation (33, 34). Optimal cell dosage, route of administration, number of injections, and therapeutic timing have yet to be determined (35), and the questions of MSC therapy's long-term effectiveness and potential tumorigenic risk have yet to be answered (36).…”

Section: Stem Cellsmentioning

confidence: 99%

Cell therapy in chronic liver disease

Nicolas

Wang

Nyberg

2016

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of review To date, the only curative treatment for end-stage liver disease is liver transplantation, which is limited by the shortage of available organs. Cell therapy, in the form of cell transplantation or cell-based extracorporeal support devices, may in the future offer an alternative to transplantation, or at least provide liver function support as a bridging therapy until surgery may be performed. The purpose of this review is to highlight the most recent advances made in the field of cell therapy and regenerative medicine for the treatment of chronic liver disease (CLD). Recent findings After hepatocyte transplantation, long-term engraftment in the liver and spleen may be achieved, which can be stimulated through preconditioning, multiple infusions, and inflammatory response blockade. Mesenchymal stem cells are promising candidates for cell transplantation, as they have been shown to reduce liver fibrosis and support endogenous regeneration. Adipose tissue-derived stem cells are also being tested in this setting, due to their ready availability. Bioartificial liver (BAL) devices are being built that allow for effective preservation of hepatocytes, and one such device has recently demonstrated survival benefit in a porcine model of liver failure. Summary Cell transplantation of primary hepatocytes or stem cell-derived hepatocyte-like cells (HLCs) for the treatment of CLD holds promise. BAL systems may in the future be able to bridge acute-on-chronic liver failure patients to liver transplantation.

show abstract

Section: Stem Cellsmentioning

confidence: 99%

Cell therapy in chronic liver disease

Nicolas

Wang

Nyberg

2016

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Although these stem cells show promise for many potential applications, data on the safety, cell regulation, and ethical aspects is limited (Coradeghini et al, 2010). Therefore, stem cells such as mesenchymal stem cells (MSCs) derived from the bone marrow Stock et al 2010;Pournasr et al 2011;Pan et al 2014), umbilical cord blood (Li et al 2009;Hong et al 2014), and adipose tissue (Al Battah et al 2011;Baer 2011;Cheng et al 2011) can be considered worthy alternatives for ESLD treatment.…”

Section: Introductionmentioning

confidence: 98%

A comparison of the chemical and liver extract-induced hepatic differentiation of adipose derived stem cells

Nhung

Nam

Nguyen

et al. 2015

In Vitro Cell.Dev.Biol.-Animal

View full text Add to dashboard Cite

Adipose-derived stem cells (ADSCs) have been put forward as promising therapeutics for end-stage liver disease (ESLD). In the present study, we compared the effects of defined chemicals and liver extract on the hepatic differentiation of ADSCs. ADSCs were isolated according to the method described in our previously published study. Subsequently, the differentiation of ADSCs was induced separately by chemicals (including hepatic growth factor (HGF), fibroblast growth factor (FGF), and oncostatin M (OSM)) and liver extract (30 μg/ml) in a total period of 21 d. The efficiency of hepatic differentiation was evaluated by changes in the cell morphology, gene expression, and cellular function. The results showed that the liver extract promoted the hepatic differentiation of ADSCs to a significantly greater extent than the chemicals. In the group of ADSCs treated with liver extract, changes in the cell morphology began sooner, and the expression of alpha-FP and albumin genes was higher than that in the chemically treated group. The ADSCs in both the groups stained positive for anti-alpha trypsin (AAT) and albumin markers. The cells also exhibited glycogen storage capacity. Therefore, we concluded that the liver extract could efficiently induce the differentiation of ADSCs into hepatocyte-like cells. This study reveals the potential of mesenchymal stem cell differentiation in the liver extract, which supports further preclinical and clinical research on the application of ADSCs in ESLD treatment.

show abstract

“…Liver transplantation is currently the only definitive therapy for decompensated cirrhosis. However, due to shortcomings such as scarcity of organ donation, high‐operational cost, lack of expertise, and centers that offer liver transplantation services, there is an urgent need to develop alternative therapies . Stem cell infusion therapy is one such alternative therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Stem cells from the BM give rise to hematopoietic stem cells (HSC) as well as stromal or mesenchymal stem cells (MSC) . Both HSC and MSC therapies have been explored in an experimental manner for both acute and chronic liver injuries, with human BM MSC showing some promise in recent reports …”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report

Rajaram

Baskar²,

Abdullah

et al. 2017

JGH Open

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC) transplant may offer an alternative to liver transplantation in patients with end‐stage liver disease. However, its efficacy remains uncertain. MSC was performed on a 50‐year‐old male with decompensated (Child‐Turcotte‐Pugh grade C) alcoholic liver cirrhosis due to an absence of donors for adult‐deceased and living‐related liver transplantation. Autologous bone marrow‐derived MSCs were harvested from the patient and cultured using standard protocols. The MSCs were subsequently re‐administrated into the liver via hepatic intra‐arterial infusion on two separate occasions. After infusion, there was an improvement in biochemical parameters (serum total bilirubin, serum albumin), and a reduction of diuretic use for ascites for up to 8 weeks. However, all biochemical and clinical parameters deteriorated on long‐term follow‐up without any further infusions. The patient eventually succumbed to his disease. MSC transplantation may have a clinical benefit on adult patients with end‐stage liver cirrhosis, but this appears to be transitory.

show abstract

Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: A meta-analysis

Abstract: BM-MSC infusion in the treatment of decompensated liver cirrhosis improved liver function. At the end of year 1, there were no serious side effects or complications.

Cited by 45 publications

References 25 publications

Cell therapy in chronic liver disease

Cell therapy in chronic liver disease

A comparison of the chemical and liver extract-induced hepatic differentiation of adipose derived stem cells

Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report

Contact Info

Product

Resources

About